Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help reverse type 2 diabetes?

NCT ID NCT07361640

Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing a Norwegian e-health program called DiaMester for adults with type 2 diabetes. The program includes digital education, coaching, and a low-calorie diet to help participants lose weight and potentially achieve diabetes remission. About 99 people will take part, and the main goal is to see how much weight they lose over the study period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
e-health lifestyle program (digital education, coaching, and diet replacement)
What this could lead to
If successful, this program could offer a scalable digital tool to help people with type 2 diabetes achieve significant weight loss and possibly remission without needing lifelong medication.
What could go wrong
This is a small pilot study, so results may not be generalizable. Weight loss and remission are challenging to maintain long-term, and the program requires high participant commitment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Men and women aged ≥ 18 years * Type 2 diabetes of duration 0-6 years (diagnosis based on 2 recorded diagnostic-level tests, HbA1c and/or blood glucose) * HbA1c ≥ 48 mmol/mol at the last routine clinical check, within last 12 months if on diet alone * HbA1c ≥ 43 mmol/mol if on treatment with oral hypoglycaemic agents or GLP-1 RA treatment * Body Mass Index (BMI) \>27 kg/m2 * Stable body weight during the last 6 months with or without the use of weight-reducing drugs * Self-reported desire to lose weight * Owns a smartphone Exclusion criteria: * Current insulin use * \> 5% weight change or started treatment with weight reducing drugs\* within the last 6 months. \*orlistat (Xenical), bupropion-naltrekson (Mysimba), fenteramin-topiramat (Qsimba), semaglutid (Wegovy, Ozempic), tirzepatid (Mounjaro), liraglutid (Saxenda, Victoza), dulaglutid (Truicity). * Recent routine HbA1c ≥108 mmol/mol * Recent eGFR \<30 ml/min/1.73 m\^2 * Known cancer * Myocardial infarction within previous 6 months * Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA) * Pregnancy/considering pregnancy or exclusively breastfeeding * Substance abuse (drugs, alcohol) * Diagnosed eating disorders or suspected ED based on screening questionnaire * Learning difficulties or unable to understand, speak and read Norwegian or English * Patients who have required hospitalization for depression or are on antipsychotic drugs * People currently participating in another clinical research trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Feeding and Eating Disorders type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Oslo University Hospital

    RECRUITING

    Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.